DUPONT ACQUIRES AMPLIGEN RIGHTS, STEPS INTO EARLY-STAGE AIDS DEVELOPMENT
Executive Summary
DUPONT ACQUIRES AMPLIGEN RIGHTS, STEPS INTO EARLY-STAGE AIDS DEVELOPMENT under an agreement with Rockville, Maryland-based HEM Research. In a May 28 press release DuPont said that it had "acquired a minority equity position in HEM Research Inc. and obtained certain rights to selected HEM products, including Ampligen, a potential AIDS drug." Ampligen, a mismatched, double-stranded RNA, is in the early stages of development as an AIDS therapeutic agent, the release notes. The patented interferon inducer was developed by scientists from Johns Hopkins and Hahnemann Universities, and previously tested in patients with kidney and colon cancer under an NCI grant ("The Pink Sheet" May 21, 1984, T&G-3). "DuPont can be very helpful to us in expanding the manufacturing and clinical capability for the development of Ampligen," HEM Research Chairman William Carter stated. "Additionally, DuPont has experience in developing and marketing diagnostics for AIDS." The company currently markets an HTLV-III antibody test kit under a joint venture with manufacturer Biotech Research. Terms of the agreement were not disclosed. HEM, a privately held company, was founded in 1966 to analyze and develop mammalian cell culture and growth media. "Subsequently, it developed compounds to stimulate or amplify the immune system and was the first company to commercially produce beta interferon," the release notes.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth